KK Kose header image

KK Kose

4922

Equity

ISIN JP3283650004 / Valor 1017515

Tokyo Stock Exchange (2024-11-21)
JPY 6,776.00+0.83%

KK Kose
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

KK Kose is a company that specializes in providing solutions aimed at optimizing the prospecting process for sales professionals. By offering tools that streamline the identification and engagement of potential leads, KK Kose positions itself as a valuable asset for individuals and organizations looking to enhance the efficiency and effectiveness of their sales strategies. The company's services are designed to reduce the time spent on prospecting, as highlighted by a user's testimonial comparing it favorably to ZoomInfo, suggesting a significant time saving of approximately 10 hours a week. This indicates that KK Kose's offerings not only focus on lead generation but also on improving the quality of leads, thereby enabling more personalized and targeted prospecting approaches.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Net Sales Growth

In the first quarter of 2024, KK Kose reported consolidated net sales of 77,583 million yen, marking a 13.8% increase compared to the same period in 2023. This growth was driven by strong sales in Japan across all segments and robust performance at Tarte, which primarily operates in the United States and Europe.

Operating Profit Increase

KK Kose's operating profit for the first quarter of 2024 rose significantly by 35.5% year-over-year, reaching 7,902 million yen. This increase was attributed to higher sales in Japan and at Tarte, along with reductions in the cost of sales ratio and SG&A expense ratio.

Ordinary Profit Surge

Ordinary profit for KK Kose in the first quarter of 2024 surged by 54.1% to 10,282 million yen. The substantial rise was primarily due to an increase in foreign exchange gains, which positively impacted the overall profitability of the company.

Profit Attributable to Owners

KK Kose reported a 78.1% increase in profit attributable to owners of the parent company for the first quarter of 2024, amounting to 6,943 million yen. This significant growth was driven by strong domestic sales and improved profitability at Tarte, despite lower sales in the China travel retail sector.

Dividend Forecast

KK Kose has maintained its dividend forecast for the fiscal year ending December 31, 2024. The company plans to distribute a total annual dividend of 140.00 yen per share, with an interim dividend of 70.00 yen and a year-end dividend of 70.00 yen, reflecting confidence in its financial stability and future outlook.

Summarized from source with an LLMView Source

Key figures

-36.4%1Y
-53.6%3Y
-62.0%5Y

Performance

43.7%1Y
39.3%3Y
37.7%5Y

Volatility

Market cap

2657 M

Market cap (USD)

Daily traded volume (Shares)

278,000

Daily traded volume (Shares)

1 day high/low

6821 / 6646

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Concentra Group Holdings Parent Inc
Concentra Group Holdings Parent Inc Concentra Group Holdings Parent Inc Valor: 136105334
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.91%USD 21.80
Bausch Health Companies Inc
Bausch Health Companies Inc Bausch Health Companies Inc Valor: 42260834
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%USD 8.18
Formycon AG
Formycon AG Formycon AG Valor: 12194189
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.17%EUR 46.50
McKesson Corp
McKesson Corp McKesson Corp Valor: 991041
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.15%USD 628.27
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.91%USD 125.10
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc Ultragenyx Pharmaceutical Inc Valor: 22860122
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.82%USD 46.02
LifeStance Health Group Inc
LifeStance Health Group Inc LifeStance Health Group Inc Valor: 111701745
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.25%USD 7.31
Nxera Pharma KK
Nxera Pharma KK Nxera Pharma KK Valor: 1892568
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.52%JPY 1,137.00
Nippon Shinyaku KK
Nippon Shinyaku KK Nippon Shinyaku KK Valor: 763041
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.38%JPY 4,154.00
Santen Seiyaku KK
Santen Seiyaku KK Santen Seiyaku KK Valor: 763395
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.15%JPY 1,664.00